Big Move for ARGX, but Do PTCT’s Margins and Growth Give It the Edge?
PTC Therapeutics (PTCT) offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs argenx (ARGX), suggesting you may be better off investing in PTCT
- PTCT’s quarterly revenue growth was 459.7%, vs. ARGX’s 97.2%.
- In addition, its Last 12 Months revenue growth came in at 91.1%, ahead of ARGX’s 83.2%.
- PTCT leads on profitability over both periods – LTM margin of 49.0% and 3-year average of -13.5%.
ARGX biotechnology company developing therapies for autoimmune diseases, including efgartigimod for multiple conditions, and immunology innovations like cusatuzumab for hematological cancers and high-risk MDS. PTCT develops and commercializes medicines for rare disorders, including treatments for Duchenne muscular dystrophy, rare diseases in Latin America, and Huntington’s disease.
Valuation & Performance Overview
| ARGX | PTCT | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 191.1 | 4.7 | PTCT |
| Revenue Growth | |||
| Last Quarter | 97.2% | 459.7% | PTCT |
| Last 12 Months | 83.2% | 91.1% | PTCT |
| Last 3 Year Average | 94.2% | 48.9% | ARGX |
| Operating Margins | |||
| Last 12 Months | 8.3% | 49.0% | PTCT |
| Last 3 Year Average | -40.1% | -13.5% | PTCT |
| Momentum | |||
| Last 3 Year Return | 89.8% | 16.2% | ARGX |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: ARGX Revenue Comparison | PTCT Revenue Comparison
See more margin details: ARGX Operating Income Comparison | PTCT Operating Income Comparison
But do these numbers tell the full story? Read Buy or Sell PTCT Stock to see if PTC Therapeutics’s edge holds up under the hood or if argenx still has cards to play.
That is one way to look at stocks. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Historical Market Performance
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| ARGX Return | 83% | 19% | 8% | 0% | 62% | 9% | 269% | <=== | |
| PTCT Return | 27% | -35% | -4% | -28% | 64% | 15% | -7% | ||
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 8% | 98% | ||
| Monthly Win Rates [3] | |||||||||
| ARGX Win Rate | 67% | 50% | 58% | 50% | 67% | 33% | 54% | ||
| PTCT Win Rate | 58% | 33% | 58% | 42% | 83% | 50% | 54% | ||
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 50% | 61% | <=== | |
| Max Drawdowns [4] | |||||||||
| ARGX Max Drawdown | -32% | -13% | -27% | -12% | -6% | -13% | -17% | ||
| PTCT Max Drawdown | -33% | -42% | -36% | -53% | -12% | -20% | -33% | ||
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | -12% | <=== | |
[1] Cumulative total returns since the beginning of 2020
[2] 2025 data is for the year till date (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read PTCT Dip Buyer Analyses and ARGX Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.